{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:49Z","timestamp":1772119429014,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Neutropenia, defined as a number of neutrophils in patients\u2019 blood specimen lower than 1500 cells\/\u03bcm\n                      <jats:sup>3<\/jats:sup>\n                      , is a common adverse event during myelosuppressive oncological chemotherapy, predisposing to febrile neutropenia (FN). Patients with coexisting moderate-to-severe chronic kidney disease (CKD) have an increased risk of FN, included in the guidelines for the primary prophylaxis of FN. However, this does not include mild kidney function impairment with estimated glomerular filtration rate (eGFR) 60\u201389 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . This prospective study analyzed the risk of neutropenia in patients on chemotherapy without indication for the primary prophylaxis of FN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study enrolled 38 patients starting chemotherapy, including 26 (68.4%) patients aged 65 years or more. The median duration of follow-up was 76 days. The methodology of creatinine assessment enabled the use of the recommended CKD-EPI formula for identifying patients with a mild reduction of glomerular filtration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen (42.1%) patients developed at least G2 neutropenia without episodes of FN. Only five (13.1%) patients had eGFR &lt; 60 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , while 15 (62.5%) eGFR &lt; 90 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . The relative risk of neutropenia in patients with impaired eGFR was over six times higher than in patients with eGFR &gt; 90 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (RR = 6.08; 95%CI:1.45\u201327.29;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our observation indicates that even a mild reduction in eGFR is a risk factor for the development of neutropenia and a potential risk factor for FN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-023-08015-8","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:02:15Z","timestamp":1693533735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A study indicates an essential link between a mild deterioration in excretory kidney function and the risk of neutropenia during cancer chemotherapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Adriana","family":"Stryczy\u0144ska-Mirocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142aw","family":"\u0141\u0105cki-Zynzeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Bor\u00f3wka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia I.","family":"Niemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander J.","family":"Owczarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Chudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"Suppl 5","key":"8015_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S1098-3597(06)80053-0","volume":"8","author":"LS Schwartzberg","year":"2006","unstructured":"Schwartzberg LS (2006) Neutropenia: etiology and pathogenesis. Clin Cornerstone 8(Suppl 5):S5\u2013S11","journal-title":"Clin Cornerstone"},{"key":"8015_CR2","unstructured":"BMJ Best Practice [Internet]. Assessment of neutropenia - differential diagnosis of symptoms. [cited 2022 Sep 29] https:\/\/bestpractice.bmj.com\/topics\/en-gb\/893"},{"issue":"9","key":"8015_CR3","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/cncr.20218","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(9):1993\u20131994","journal-title":"Cancer"},{"key":"8015_CR4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Common Terminology Criteria for Adverse Events (CTCAE) V5.0; 2017. [cited 2022 Sep 29] https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"3","key":"8015_CR5","doi-asserted-by":"publisher","first-page":"00165","DOI":"10.15406\/jcpcr.2016.05.00165","volume":"5","author":"A Rasmy","year":"2016","unstructured":"Rasmy A, Amal A, Fotih S, Selwi W (2016) Febrile Neutropenia in Cancer Patient: Epidemiology, Microbiology, Pathophysiology and Management. J Cancer Prev Curr Res 5(3):00165. https:\/\/doi.org\/10.15406\/jcpcr.2016.05.00165","journal-title":"J Cancer Prev Curr Res"},{"issue":"8","key":"8015_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist 27(8):625\u2013636. https:\/\/doi.org\/10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"issue":"suppl 5","key":"8015_CR7","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v118","journal-title":"Ann Oncol"},{"issue":"14","key":"8015_CR8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):1443\u20131453","journal-title":"J Clin Oncol"},{"issue":"3","key":"8015_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"8015_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/1042819031000119262","volume":"44","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M et al (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44(12):2069\u20132076","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"8015_CR11","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OAC Clark","year":"2005","unstructured":"Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23(18):4198\u20134214","journal-title":"J Clin Oncol"},{"issue":"11","key":"8015_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"23","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 23(11):404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"issue":"21","key":"8015_CR13","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol"},{"issue":"10","key":"8015_CR14","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1681\/ASN.2013060604","volume":"25","author":"WT Lowrance","year":"2014","unstructured":"Lowrance WT, Ordo\u00f1ez J, Udaltsova N, Russo P, Go AS (2014) CKD and the risk of incident cancer. J Am Soc Nephrol 25(10):2327\u20132334","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"8015_CR15","doi-asserted-by":"publisher","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","volume":"1","author":"V Launay-Vacher","year":"2016","unstructured":"Launay-Vacher V, Janus N, Deray G (2016) Renal insufficiency and cancer treatments. ESMO Open 1(4):e000091","journal-title":"ESMO Open"},{"issue":"10246","key":"8015_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","volume":"396","author":"J Malyszko","year":"2020","unstructured":"Malyszko J, Tesarova P, Capasso G, Capasso A (2020) The link between kidney disease and cancer: complications and treatment. Lancet 396(10246):277\u2013287","journal-title":"Lancet"},{"key":"8015_CR17","doi-asserted-by":"publisher","unstructured":"Flombaum CD (2010) Nephrotoxicity of chemotherapy agents and chemotherapy administration in patients with renal disease. In: Cohen EP (ed) Cancer and the Kidney: The frontier of nephrology and oncology, 2nd edn. Oxford Clinical Nephrology Series. https:\/\/doi.org\/10.1093\/med\/9780199580194.003.0005","DOI":"10.1093\/med\/9780199580194.003.0005"},{"key":"8015_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","volume":"72","author":"K Kashani","year":"2020","unstructured":"Kashani K, Rosner MH, Ostermann M (2020) Creatinine: from physiology to clinical application. Eur J Intern Med 72:9\u201314","journal-title":"Eur J Intern Med"},{"issue":"24","key":"8015_CR19","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","volume":"35","author":"T Janowitz","year":"2017","unstructured":"Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ et al (2017) New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol 35(24):2798\u20132805","journal-title":"J Clin Oncol"},{"issue":"19","key":"8015_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749","journal-title":"N Engl J Med"},{"issue":"12","key":"8015_CR21","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1681\/ASN.2021070988","volume":"32","author":"C Delgado","year":"2021","unstructured":"Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR (2021) A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol 32(12):2994\u20133015. https:\/\/doi.org\/10.1681\/ASN.2021070988","journal-title":"J Am Soc Nephrol"},{"key":"8015_CR22","unstructured":"Kidney profile urine albumin, and the urine albumin-creatinine ratio - cap. [Internet]. [cited 2022 Sep 29] https:\/\/documents.cap.org\/documents\/2020-a-kidney-biomarkers.pdf"},{"issue":"9","key":"8015_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604","journal-title":"Ann Intern Med"},{"issue":"15","key":"8015_CR24","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453","journal-title":"Eur J Cancer"},{"issue":"4","key":"8015_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3181\/00379727-13-45","volume":"13","author":"DD Bois","year":"1916","unstructured":"Bois DD, Bois EFD (1916) A height-weight formula to estimate the surface area of man. Exp Biol Med (Maywood) 13(4):77\u201378","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"8015_CR26","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Jane HS (2014) Age and cancer risk. Am J Prev Med 46(3):S7\u2013S15","journal-title":"Am J Prev Med"},{"issue":"9","key":"8015_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/annonc\/mdw259","volume":"27","author":"O Le Saux","year":"2016","unstructured":"Le Saux O, Falandry C, Gan HK, You B, Freyer G, P\u00e9ron J (2016) Inclusion of elderly patients in oncology clinical trials. Ann Oncol 27(9):1799\u20131804","journal-title":"Ann Oncol"},{"issue":"6","key":"8015_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3747\/co.22.2623","volume":"22","author":"T Hsu","year":"2015","unstructured":"Hsu T, Chen R, Lin SCX, Djalalov S, Horgan A, Le LW et al (2015) Pilot of three objective markers of physical health and chemotherapy toxicity in older adults. Curr Oncol 22(6):385\u2013391","journal-title":"Curr Oncol"},{"issue":"4","key":"8015_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1191\/1078155201jp084oa","volume":"7","author":"M Wilson-Royalty","year":"2001","unstructured":"Wilson-Royalty M, Lawless G, Palmer C, Brown R (2001) Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract 7(4):141\u2013147","journal-title":"J Oncol Pharm Pract"},{"issue":"2 Suppl","key":"8015_CR30","first-page":"1","volume":"8","author":"L Balducci","year":"2001","unstructured":"Balducci L (2001) The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8(2 Suppl):1\u201328","journal-title":"Cancer Control"},{"issue":"317","key":"8015_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijcard.2020.04.080","volume":"15","author":"J-C Youn","year":"2020","unstructured":"Youn J-C, Chung W-B, Ezekowitz JA, Hong JH, Nam H, Kyoung D-S et al (2020) Cardiovascular disease burden in adult patients with cancer: an 11-year nationwide population-based cohort study. Int J Cardiol 15(317):167\u2013173","journal-title":"Int J Cardiol"},{"issue":"2","key":"8015_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdq609","volume":"22","author":"M Aapro","year":"2011","unstructured":"Aapro M, Bernard-Marty C, Brain EGC, Batist G, Erdkamp F, Krzemieniecki K et al (2011) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 22(2):257\u2013267","journal-title":"Ann Oncol"},{"issue":"1","key":"8015_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"8015_CR34","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","volume":"25","author":"C Chao","year":"2014","unstructured":"Chao C, Page JH, Yang S-J, Rodriguez R, Huynh J, Chia VM (2014) History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol 25(9):1821\u20131829","journal-title":"Ann Oncol"},{"issue":"1","key":"8015_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.esmoop.2020.100038","volume":"6","author":"M Aapro","year":"2021","unstructured":"Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6(1):1","journal-title":"ESMO Open"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08015-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:13:37Z","timestamp":1694754817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8015"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08015-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2492981\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The last sentence in the abstract is removed as it was included in error.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Bioethics Committee of the Medical University of Silesia in Katowice (KNW\/022\/KB1\/24\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No identifying data or images from any individual participant was included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"549"}}